Royal Fund Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Royal Fund Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3	Closed	–	–	230
2020 Q1	$0	Hold	3	–	–	﹤0.01%	588
2019 Q4	$0	Buy	+3	New	+$443	﹤0.01%	635

Other funds holding CRBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Fund Management's CRBP Position: Q2 2020 in Review

Royal Fund Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2020, closing a stake of 3 shares.

Royal Fund Management first reported a position in CRBP in Q4 2019 and held it in 2 quarters. The position peaked at $0 in Q1 2020. 140 funds tracked by Wall St. Rank hold CRBP as of Q2 2020.

Royal Fund Management reported no remaining Corbus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Royal Fund Management sold 3 Corbus Pharmaceuticals shares in Q2 2020.
Royal Fund Management first reported a position in Corbus Pharmaceuticals in Q4 2019 and held it in 2 quarters.
Royal Fund Management's Corbus Pharmaceuticals position peaked at $0 in Q1 2020.
140 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.